Total Credits: .75 including .75 AOA Category 1-A Credit(s)
This program will expire and must be completed by 11/26/24.
Physicians and medical professionals will learn why long-term randomized clinical trials against placebo were done to verify the cardiovascular safety of novel hypoglycemic agents. They will compare and contrast outcomes in randomized clinical trials for sodium-glucose-linked transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors for cardiovascular or renal endpoints. They will be able to name the pharmacological agents (and their indications) that have received FDA approval for "benefits beyond glucose-lowering" with regard to preventing cardiovascular or renal endpoints.
Learning Objectives:
• Explain why long-term randomized clinical trials against placebo were done to verify the cardiovascular safety of novel hypoglycemic agents
• Compare and contrast outcomes in randomized clinical trials for sodium-glucose linked transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors for cardiovascular or renal endpoints
• Name the pharmacological agents (and their indications) that have received FDA approval for "benefits beyond glucose-lowering" with regard to preventing cardiovascular or renal endpoints
Accreditation Statement:
The Montana Osteopathic Medical Association is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians and designates this program for a maximum of .75 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation in this activity.
Planning Disclosure:
The Montana Osteopathic Medical Association Education Planning Committee has no relevant financial relationships with any organization producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients relative to the content of this presentation.
Grievance Policy:
All grievances should be in writing and should specify the nature of the grievance. Initially, all grievances should be directed to MOMA Executive Director, who will then forward said grievance to the Education & Convention Committee. All grievances will receive an initial response in writing within 30 days of receipt. If the participant does not receive a satisfactory response, then they can then submit a complaint in writing to the Bureau of Osteopathic Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.
| Cardiovascular & Renal Proetection with Sodium-Glucose (2.6 MB) | 14 Pages | Available after Purchase |
William J. Elliott, MD, PhD is Chair of the Department of Biomedical Sciences, and Professor of Preventive Medicine, Internal Medicine, and Pharmacology at Pacific Northwest University of Health Sciences in Yakima, WA. Dr. Elliott received his MD and PhD from the University of Chicago and trained in Internal Medicine and Pharmacology at Washington University-St. Louis. He holds Board Certification in Internal Medicine and Clinical Pharmacology and is a “Specialist in Clinical Hypertension.”